The shares of commercial-stage medical tool manufacturer Ra Medical Systems (RMED) have tumbled 92.7% in rate over the past year as a result of financier issues surrounding the company’s inadequate monetary wellness. Additionally, provided the unpredictability bordering the FDA’s authorization of its DABRA catheter laser system, the inquiry comes to be, is the penny stock a winner now? Keep reading, allow’s figure out.

Medical tool business Ra Medical Systems, Inc. (RMED – Obtain Ranking) in Carlsbad, Calif., is designs, creates, as well as markets excimer lasers to deal with vascular conditions. The firm has actually made substantial progression in vital initiatives, including its DABRA innovation laser system as well as atherectomy crucial clinical research. However, the RMED stock price has declined 86.8% in rate over the past 6 months as well as 92.7% over the past year, reflecting investor problems over its disappointing revenue and also revenues development and also the sale of its dermatology service.

Closing the other day’s session at $0.42, the stock is presently trading 95.7% below its 52-week high of $9.82, suggesting bearish view.

While the commercial-stage medical gadget company has actually submitted a 510( k) application with the U.S. Food and Drug Administration (FDA) for its DABRA catheter, its commercialization leads continue to be unpredictable up until its product receives approval from the FDA. Furthermore, the stock’s negative success can make capitalists nervous.

Marketing Shares

Last month, RMED valued an underwritten public offering of units of its ordinary shares, consisting of warrants to buy up to 27.6 million shares of the common stock as well as pre-funded warrants to buy approximately 14.47 shares of penny stocks. The medical tool supplier expects roughly $12.1 million in gross proceeds from the offering.

Divestiture of Dermatology Company

Leading 10 Stocks for 2022
In the 3rd quarter, RMED completed the sale of its Pharos dermatology organization for internet profits of roughly $3.5 million. This was done as a part of the business’s plans to focus its sources on the market for medical tools to deal with peripheral artery condition (PAD). However, the divestiture can negatively influence the medical device manufacturer’s earnings and expense structure in the near term as well as cause RMED’s stock rate to tumble better.

Stark Earnings

The company’s trailing-12-month ROA and cash from operations are negative 100.6% as well as $31.33 million, specifically. Furthermore, its trailing-12-month gross profit margin, ROE and ROTC are adverse 18.9%, 115%, and also 67%, specifically. And its 0.12% property turnover proportion is 65.2% lower than the 0.34% industry standard.

Faltering Financials
RMED’s net income from proceeding procedures came in at $5,000 for the third quarter, finished Sept. 30, 2021, versus $68,000 in the third quarter of 2020. Its gross loss stood at $24,000 for the quarter, while operating loss came in at $7.39 million. Moreover, its net loss totaled up to $4.3 million, while its loss per share came in at $0.67. RMED reported an adverse modified EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. And also its complete overhead expanded 2.1% year-over-year to $7.15 million throughout this period.

POWR Ratings Mirror Bleak Leads

RMED has a general D score, which converts to Offer in our POWR Ratings system. The POWR Rankings are calculated by thinking about 118 unique factors, with each element heavy to an optimum degree.

Our exclusive score system additionally examines each stock based upon 8 distinct groups. RMED has an F quality for Quality. This reflects the stock’s negative ROA as well as cash flow from operations.

The company has a D grade in Momentum, regular with its cost decrease over the past six months. Additionally, it has an F grade for Security, which is in sync with its relatively high beta of 1.65.

Beyond the grades I have actually highlighted, one can look into additional RMED scores for Sentiment, Development, and also Value right here. Amongst the 166 stocks in the D-rated Medical– Devices & Equipment industry, RMED is ranked # 119.


Analysts expect RMED’s EPS to remain negative this year. While its initiatives to create DABRA catheters bode well, its negative profit margin and insufficient monetary strength can cause its shares to decline even more. Furthermore, the uncertainty bordering the regulative clearance and also commercialization of its DABRA laser system could increase capitalists’ problems. So, we think it is ideal avoided now.

Exactly How Does Ra Medical Systems (RMED) Compare To its Peers?

While RMED has a general D (Sell) score in our exclusive ranking system, one might intend to consider having a look at its market peers, Fonar Firm (FONR – Obtain Ranking), Electromed, Inc. (ELMD – Obtain Ranking), as well as Abbott Laboratories (ABT – Obtain Rating), having an A (Strong Buy) score.